|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4801575A
(en)
|
1986-07-30 |
1989-01-31 |
The Regents Of The University Of California |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5180820A
(en)
|
1989-08-30 |
1993-01-19 |
Barde Yves Alain |
Brain-derived neurotrophic factor
|
|
US5229500A
(en)
|
1989-08-30 |
1993-07-20 |
Regeneron Pharmaceuticals, Inc. |
Brain derived neurotrophic factor
|
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
US5182107A
(en)
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
US5977307A
(en)
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
|
US5672683A
(en)
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
US5154924A
(en)
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
ATE194384T1
(de)
|
1989-09-12 |
2000-07-15 |
Hoffmann La Roche |
Tnf-bindende proteine
|
|
US5527288A
(en)
|
1990-12-13 |
1996-06-18 |
Elan Medical Technologies Limited |
Intradermal drug delivery device and method for intradermal delivery of drugs
|
|
TW279133B
(https=)
|
1990-12-13 |
1996-06-21 |
Elan Med Tech |
|
|
US6060069A
(en)
|
1991-05-20 |
2000-05-09 |
Dura Pharmaceuticals, Inc. |
Pulmonary delivery of pharmaceuticals
|
|
US6287792B1
(en)
|
1991-06-17 |
2001-09-11 |
The Regents Of The University Of California |
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
|
|
DE69230545T2
(de)
|
1991-08-21 |
2000-07-06 |
Novartis Ag, Basel |
Antikörperderivate
|
|
MX9205293A
(es)
|
1991-09-20 |
1993-05-01 |
Syntex Sinergen Neuroscience J |
Factores neurotrofico derivado del glial
|
|
JPH06228199A
(ja)
|
1992-11-27 |
1994-08-16 |
Takeda Chem Ind Ltd |
血液脳関門通過可能なペプチド結合体
|
|
CA2115900A1
(en)
|
1993-02-22 |
1994-08-23 |
Gerald W. Becker |
Pharmaceutical screens and antibodies
|
|
US5997501A
(en)
|
1993-11-18 |
1999-12-07 |
Elan Corporation, Plc |
Intradermal drug delivery device
|
|
ES2167391T3
(es)
|
1994-09-16 |
2002-05-16 |
Merck Patent Gmbh |
Inmunoconjugados ii.
|
|
US5656284A
(en)
|
1995-04-24 |
1997-08-12 |
Balkin; Michael S. |
Oral transmucosal delivery tablet and method of making it
|
|
AU6163196A
(en)
|
1995-06-07 |
1996-12-30 |
Smithkline Beecham Corporation |
Method for obtaining receptor agonist antibodies
|
|
DK0851753T3
(da)
|
1995-09-19 |
2004-03-15 |
Fujisawa Pharmaceutical Co |
Aerosolpræparater
|
|
US6015662A
(en)
|
1996-01-23 |
2000-01-18 |
Abbott Laboratories |
Reagents for use as calibrators and controls
|
|
US5837231A
(en)
|
1996-06-27 |
1998-11-17 |
Regents Of The University Of Minnesota |
GM-CSF administration for the treatment and prevention of recurrence of brain tumors
|
|
JP3338061B2
(ja)
|
1996-07-16 |
2002-10-28 |
オランダ国 |
ジベンゾジヒドロピリジンカルボン酸エステル類及びそれらの化学ルミネセント分析法への利用
|
|
US8173127B2
(en)
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
|
AU8269898A
(en)
|
1997-06-27 |
1999-01-19 |
Regents Of The University Of California, The |
Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
|
|
WO1999000951A1
(en)
|
1997-06-30 |
1999-01-07 |
Motorola Inc. |
Circuit and packet switched network interconnection
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US6482923B1
(en)
|
1997-09-17 |
2002-11-19 |
Human Genome Sciences, Inc. |
Interleukin 17-like receptor protein
|
|
US6016800A
(en)
|
1997-10-24 |
2000-01-25 |
Century; Theodore J. |
Intrapulmonary aerosolizer
|
|
US6165783A
(en)
|
1997-10-24 |
2000-12-26 |
Neuro Spheres Holdings Ltd. |
Erythropoietin-mediated neurogenesis
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
DE69839969D1
(de)
|
1997-12-11 |
2008-10-16 |
Alza Corp |
Vorrichtung zur verbesserung des transdermalen flusses von medikamenten
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
WO1999066951A2
(en)
|
1998-06-22 |
1999-12-29 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
|
US6348210B1
(en)
|
1998-11-13 |
2002-02-19 |
Alza Corporation |
Methods for transdermal drug administration
|
|
US6375975B1
(en)
|
1998-12-21 |
2002-04-23 |
Generex Pharmaceuticals Incorporated |
Pharmaceutical compositions for buccal and pulmonary application
|
|
WO2000037502A2
(en)
|
1998-12-22 |
2000-06-29 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists and uses thereof
|
|
US6284262B1
(en)
|
1999-01-26 |
2001-09-04 |
Virgil A. Place |
Compact dosage unit for buccal administration of a pharmacologically active agent
|
|
US7214658B2
(en)
|
2004-07-06 |
2007-05-08 |
Tact Ip, Llc |
Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
|
|
BR0009247A
(pt)
|
1999-03-05 |
2001-11-20 |
Epigenesis Pharmaceuticals Inc |
Método para validar/invalidar alvo(s) e vias
|
|
US7410941B1
(en)
|
1999-04-13 |
2008-08-12 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
|
|
WO2000077178A1
(en)
|
1999-06-16 |
2000-12-21 |
Boston Biomedical Research Institute |
IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
|
|
CZ299516B6
(cs)
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
|
US20020052311A1
(en)
|
1999-09-03 |
2002-05-02 |
Beka Solomon |
Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
|
|
JP3589912B2
(ja)
|
1999-09-03 |
2004-11-17 |
泰久 福井 |
ホスファチジルイノシトール−３，４−二リン酸を認識するモノクローナル抗体
|
|
US6195605B1
(en)
|
1999-09-29 |
2001-02-27 |
Bmi Technologies Inc. |
Impact monitor
|
|
US6585971B1
(en)
*
|
1999-11-12 |
2003-07-01 |
Harbor-Ucla Research And Education Institute |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
|
|
EP1239869B1
(en)
|
1999-12-20 |
2013-08-28 |
Immunex Corporation |
Tweak receptor
|
|
US6248262B1
(en)
|
2000-02-03 |
2001-06-19 |
General Electric Company |
Carbon-reinforced thermoplastic resin composition and articles made from same
|
|
WO2001064878A2
(en)
|
2000-02-29 |
2001-09-07 |
Lexicon Genetics Incorporated |
Human transporter proteins and polynucleotides encoding the same
|
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
|
US6696274B2
(en)
|
2000-05-03 |
2004-02-24 |
Supratek Pharma, Inc. |
Ligand for enhancing oral and CNS delivery of biological agents
|
|
US7078376B1
(en)
|
2000-08-11 |
2006-07-18 |
Baxter Healthcare S.A. |
Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
|
|
US20030165853A1
(en)
|
2000-12-04 |
2003-09-04 |
The Regents Of The University Of California Office Of Technology Transfer |
Antisense imaging of gene expression of the brain in vivo
|
|
DK1471871T3
(da)
|
2001-02-02 |
2007-09-17 |
Ortho Mcneil Pharm Inc |
Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin
|
|
EP1360200A2
(en)
|
2001-02-06 |
2003-11-12 |
MERCK PATENT GmbH |
Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
|
|
US8163289B2
(en)
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
|
US20040005309A1
(en)
|
2002-05-29 |
2004-01-08 |
Symbiontics, Inc. |
Targeted therapeutic proteins
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
US7629309B2
(en)
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
ATE384736T1
(de)
|
2001-04-30 |
2008-02-15 |
Zystor Therapeutics Inc |
Subzelluläres targeting von therapeutischen proteinen
|
|
JP4202250B2
(ja)
|
2001-07-25 |
2008-12-24 |
バイオマリン ファーマシューティカル インコーポレイテッド |
血液脳関門輸送を調節するための組成物および方法
|
|
PT1944040E
(pt)
|
2001-08-17 |
2012-10-31 |
Univ Washington |
Método de avaliação para a doença de alzheimer
|
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
WO2003032913A2
(en)
|
2001-10-16 |
2003-04-24 |
Symbiontics Inc. |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
US7053202B2
(en)
|
2001-10-19 |
2006-05-30 |
Millennium Pharmaceuticals, Inc. |
Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
|
|
CA2487815A1
(en)
|
2002-05-29 |
2003-12-11 |
Biomarin Pharmaceutical Inc. |
Targeted therapeutic proteins
|
|
ES2263984T3
(es)
|
2002-06-28 |
2006-12-16 |
Domantis Limited |
Ligandos doble-especificos con una vida media serica aumentada.
|
|
US20050142141A1
(en)
*
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
US20040102369A1
(en)
|
2002-11-27 |
2004-05-27 |
The Regents Of The University Of California |
Transport of basic fibroblast growth factor across the blood brain barrier
|
|
US7388079B2
(en)
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
EP2325301B1
(en)
|
2003-02-11 |
2015-09-02 |
Shire Human Genetic Therapies, Inc. |
Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
|
|
WO2004108071A2
(en)
|
2003-06-05 |
2004-12-16 |
Salk Institute For Biological Studies |
Targeting polypeptides to the central nervous system
|
|
US20050026823A1
(en)
*
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
CA2529945A1
(en)
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
|
US7294704B2
(en)
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
|
EP1548031A1
(en)
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Nature-identical erythropoietin
|
|
US8536315B2
(en)
|
2004-01-30 |
2013-09-17 |
Shire Pharmaceuticals Ireland Limited |
Production and purification of recombinant arylsulftase
|
|
CN1922313B
(zh)
|
2004-02-10 |
2011-10-26 |
生物马林医药公司 |
酸性α-糖苷酶及其片段
|
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
US7906625B2
(en)
|
2005-01-24 |
2011-03-15 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
|
EP1877099B1
(en)
|
2005-04-06 |
2012-09-19 |
Genzyme Corporation |
Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
|
|
EP2177614B1
(en)
|
2005-05-02 |
2014-12-31 |
Toray Industries, Inc. |
Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
|
|
WO2007019232A2
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
CA2619725C
(en)
|
2005-08-18 |
2016-06-07 |
Ramot At Tel Aviv University Ltd. |
Single chain antibodies against beta-amyloid peptide
|
|
US20090047338A1
(en)
|
2005-10-05 |
2009-02-19 |
Immune Disease Institute, Inc. |
Method to Treat Flavivirus Infection with siRNA
|
|
US8053569B2
(en)
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
|
US8741260B2
(en)
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
|
US8124095B2
(en)
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
|
BRPI0617688A2
(pt)
*
|
2005-10-21 |
2011-06-07 |
Hoffmann La Roche |
método para expressão recombinante de um polipeptìdeo
|
|
EP1981546B1
(en)
|
2006-02-06 |
2014-06-04 |
The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center |
Enzyme replacement therapy for treating lysosomal storage diseases
|
|
AU2007256639A1
(en)
|
2006-06-07 |
2007-12-13 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
|
US7981417B2
(en)
|
2006-06-07 |
2011-07-19 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting anti-bodies
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
WO2008022349A2
(en)
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
WO2008051854A2
(en)
|
2006-10-20 |
2008-05-02 |
Trustees Of Boston University |
A tunable genetic switch for regulating gene expression
|
|
CN101678079B
(zh)
|
2006-11-28 |
2013-12-25 |
韩诺生物制约株式会社 |
修饰的促红细胞生成素多肽及其治疗用途
|
|
DE202007003495U1
(de)
*
|
2007-03-08 |
2007-07-05 |
Rieter Automatik Gmbh |
Vorrichtung zur Erzeugung von Granulatkörnern aus einer Kunststoffschmelze
|
|
WO2008151841A2
(en)
|
2007-06-15 |
2008-12-18 |
University Of Zurich |
Treatment for alzheimer' s disease
|
|
AU2008282496B2
(en)
|
2007-07-27 |
2013-04-04 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-iduronidase activity in the CNS
|
|
WO2009070597A2
(en)
|
2007-11-26 |
2009-06-04 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of gdnf to the cns
|
|
HRP20170698T1
(hr)
|
2008-05-07 |
2017-09-22 |
Biomarin Pharmaceutical Inc. |
Lizosomski usmjereni peptidi i njihove uporabe
|
|
EA019512B1
(ru)
|
2008-07-02 |
2014-04-30 |
Эмерджент Продакт Дивелопмент Сиэтл, Ллс |
Il-6-опосредованная иммунотерапия
|
|
US20100077498A1
(en)
|
2008-09-11 |
2010-03-25 |
Pardridge William M |
Compositions and methods for blood-brain barrier delivery in the mouse
|
|
US20100098693A1
(en)
|
2008-10-07 |
2010-04-22 |
Pardridge William M |
Compositions and methods for blood-brain barrier delivery of organophosphatases
|
|
WO2010069074A1
(en)
|
2008-12-17 |
2010-06-24 |
Universite Du Quebec A Montreal |
Membrane type-1 matrix metalloprotein inhibitors and uses thereof
|
|
CA2748889A1
(en)
|
2009-03-18 |
2010-09-23 |
Armagen Technologies, Inc. |
Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
|
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
|
JP2013507131A
(ja)
|
2009-10-09 |
2013-03-04 |
アーメイゲン・テクノロジーズ・インコーポレイテッド |
Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
|
|
RS62620B1
(sr)
|
2010-06-25 |
2021-12-31 |
Shire Human Genetic Therapies |
Metode i kompozicije za isporuku cns akrilsulfataze a
|
|
NZ605874A
(en)
|
2010-06-25 |
2015-02-27 |
Shire Human Genetic Therapies |
Methods and compositions for cns delivery of heparan n-sulfatase
|
|
CN103179980B
(zh)
|
2010-06-25 |
2016-09-28 |
夏尔人类遗传性治疗公司 |
艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物
|
|
CA2805449A1
(en)
|
2010-06-25 |
2011-12-29 |
Shire Human Genetic Therapies, Inc. |
Treatment of sanfilippo syndrome type b
|
|
AR084020A1
(es)
|
2010-11-30 |
2013-04-17 |
Genentech Inc |
Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
|
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
WO2012177997A1
(en)
|
2011-06-22 |
2012-12-27 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
US8859256B2
(en)
|
2011-10-05 |
2014-10-14 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
JP6329483B2
(ja)
|
2011-10-12 |
2018-05-23 |
シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． |
組換えヒトｎａｇｌｕタンパク質およびその利用
|
|
AU2012346448B2
(en)
|
2011-12-02 |
2017-09-14 |
Armagen, Inc. |
Methods and compositions for increasing arylsulfatase A activity in the CNS
|
|
WO2013181454A1
(en)
|
2012-05-30 |
2013-12-05 |
Biostrategies LC |
Plant lectins as carriers of associated drug substances into animal and human cells
|
|
KR101380740B1
(ko)
|
2012-06-29 |
2014-04-11 |
쉐어 휴먼 제네텍 세러피스, 인코포레이티드 |
이듀로네이트-2-설파타제의 정제
|
|
CN104684928A
(zh)
|
2012-08-02 |
2015-06-03 |
Jn生物科学有限责任公司 |
通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
|
|
RU2015118580A
(ru)
|
2012-10-19 |
2016-12-10 |
Токусима Юниверсити |
НОВЫЙ ВЫСОКО ФУНКЦИОНАЛЬНЫЙ ФЕРМЕНТ, ИМЕЮЩИЙ МОДИФИЦИРОВАННУЮ СУБСТРАТНУЮ СПЕЦИФИЧНОСТЬ β-ГЕКСОЗАМИНИДАЗЫ ЧЕЛОВЕКА И ПРОЯВЛЯЮЩИЙ УСТОЙЧИВОСТЬ К ПРОТЕАЗЕ
|
|
US20140354655A1
(en)
|
2013-06-04 |
2014-12-04 |
Qualcomm Mems Technologies, Inc. |
Reducing floating node leakage current with a feedback transistor
|
|
WO2015009961A1
(en)
|
2013-07-19 |
2015-01-22 |
Armagen Technologies, Inc. |
Compositions and methods related to structures that cross the blood brain barrier
|
|
JP6692293B2
(ja)
|
2013-07-22 |
2020-05-13 |
アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． |
Ｃｎｓにおける酵素活性を増大するための方法および組成物
|
|
US10400227B2
(en)
|
2014-03-17 |
2019-09-03 |
The University Of Manitoba |
β-hexosaminidase protein variants and associated methods for treating GM2 gangliosidoses
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
TWI761413B
(zh)
|
2016-12-26 |
2022-04-21 |
日商Ｊｃｒ製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
US10940185B2
(en)
|
2016-12-28 |
2021-03-09 |
Jcr Pharmaceuticals Co., Ltd. |
Lyophilized preparation
|